Marker Therapeutics, Inc. SEC filings MRKR
Marker Therapeutics, Inc. has 904 filings in SEC EDGAR's recent list, going back to Sep 3, 1999. Its latest annual report, Form ARS, was filed on Mar 20, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Mar 20, 2026 | — |
| DEF 14A | Proxy statement | Mar 20, 2026 | May 1, 2026 |
| PRE 14A | Preliminary proxy statement | Mar 10, 2026 | May 1, 2026 |
| DEFA14A | Additional proxy material | Apr 24, 2025 | — |
| DEF 14A | Proxy statement | Apr 24, 2025 | Jun 6, 2025 |
| DEFA14A | Additional proxy material | Feb 4, 2025 | — |
| DEF 14A | Proxy statement | Feb 4, 2025 | Mar 21, 2025 |
| PRE 14A | Preliminary proxy statement | Jan 13, 2025 | Mar 21, 2025 |
| DEF 14A | Proxy statement | Apr 26, 2024 | Jun 6, 2024 |
| DEF 14A | Proxy statement | Apr 28, 2023 | Jun 6, 2023 |
| DEF 14A | Proxy statement | Apr 15, 2022 | May 24, 2022 |
| PRE 14A | Preliminary proxy statement | Apr 6, 2022 | May 24, 2022 |
| DEFA14A | Additional proxy material | Apr 23, 2021 | — |
| DEF 14A | Proxy statement | Apr 23, 2021 | Jun 8, 2021 |
| DEF 14A | Proxy statement | Apr 17, 2020 | May 19, 2020 |
| DEFA14A | Additional proxy material | Mar 28, 2019 | — |
| DEF 14A | Proxy statement | Mar 28, 2019 | May 9, 2019 |
| DEFM14A | Filing | Sep 14, 2018 | — |
| DEFA14A | Additional proxy material | Aug 8, 2018 | — |
| PREM14A | Filing | Jul 13, 2018 | Jul 13, 2018 |
| DEFA14A | Additional proxy material | May 15, 2018 | — |
| DEF 14A | Proxy statement | Jul 12, 2017 | Aug 29, 2017 |
| DEF 14C | Information statement | Jan 28, 2014 | Jan 28, 2014 |
| PRE 14C | Filing | Jan 17, 2014 | Jan 17, 2014 |
| DEF 14C | Information statement | Jan 29, 2010 | Jan 29, 2010 |
| PRE 14C | Form 14c | Jan 6, 2010 | Jan 6, 2010 |
| DEF 14A | Proxy statement | Dec 30, 2008 | Dec 30, 2008 |
| PRE 14A | Preliminary proxy statement | Dec 10, 2008 | Dec 10, 2008 |
| DEF 14A | Proxy statement | Mar 2, 2007 | Feb 28, 2007 |
| PRE 14A | Preliminary proxy statement | Feb 16, 2007 | Feb 16, 2007 |
| DEFA14A | Additional proxy material | Mar 26, 2004 | — |
| DEF 14A | Proxy statement | Mar 16, 2004 | Dec 31, 2003 |
| PRE 14A | Preliminary proxy statement | Mar 5, 2004 | Dec 31, 2003 |
| DEF 14C | Information statement | Jun 17, 2002 | Jul 15, 2002 |
| PRE 14C | Preliminary information statement | May 31, 2002 | Jul 19, 2002 |
Showing 35 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MRKR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1094038
- Former names
- TAPIMMUNE INC. (until Oct 17, 2018); TAPIMMUNE INC (until Jun 29, 2017); GENEMAX CORP (until Jun 28, 2007); EDUVERSE COM (until Jun 17, 2002)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.